Skip to main content
News > News > Raymond Scalettar, MD, DSc, Appointed To Bacterial Robotics Science Directorate

Raymond Scalettar, MD, DSc, Appointed To Bacterial Robotics Science Directorate

Dr. Scalettar will advise on unique and innovative therapeutic product development

CINCINNATI, OH. – April 21, 2014 – Bacterial Robotics is a life science biotechnology firm.  The Company uses synthetic biology tools in an evolutionary engineering approach to develop bacterial robots, or BactoBotsToday, the Company announced the appointment of Dr. Ray Scalettar to its Scientific Directorate.

The Company is developing unique therapeutic BactoBots.  Dr. Scalettar’s immunological and entrepreneurial expertise will provide important guidance for certain product developments for clinical applications.

Jason E. Barkeloo, CEO stated, “Dr. Scalettar is significantly recognized for clinical and community accomplishments.  We are fortunate to have attracted his guidance and expertise.  As a Master of the American College of Rheumatology, and former member of the Advisory Council of the National Institutes of Arthritis Musculoskeletal and Skin Diseases, Ray is ideally situated to provide us immunological product development guidance.”

Dr. Scalettar is a Health Policy Consultant and Practicing Physician.  He is also a Clinical Professor of Medicine, at the George Washington University Medical Center.  Dr. Scalettar is also a Former Chair, Board of Trustees, of the American Medical Association.

Entrepreneurially, Dr. Scalettar co-Founded and was the Director of National Capital Reciprocal Insurance, a Professional Liability Company.

Barkeloo added, “We are focused upon creating innovative products and intellectual property.  Dr. Scalettar is a proven medical leader.  His expertise will help Bacterial Robotics reduce product development risks by ensuring end-usage is engineered into the product from the outset of development.”

VIEW .PDF VERSION OF PRESS RELEASE

About Bacterial Robotics

An early developer in the emerging synthetic biology industry, Bacterial Robotics is headquartered in Winchester, Ohio (USA).  It has operations in Cincinnati, OH and Covington, KY.  The Company specializes in identifying markets for developing and deploying BactoBots™ and ViruBots™; microscopic organism-based robots that produce, build, sense, and perform functions.

The Company’s products are protected by a proprietary genetics rights management (GeRM™) key system.  The GeRM system is a consumable additive that prevents the BactoBots against theft or release.  The GeRM key consumable enables the Company to gain revenues from licensing the manufacture and distribution of its BactoBots.

Once Bacterial Robotics develops a BactoBot, it creates a go-to-market subsidiary to launch the product.  Pilus Energy was the Company’s first subsidiary, a wastewater-to-value company.  That subsidiary was merged with Tauriga Sciences, Inc. (OTCQB: TAUG) in January 2014.

For more information on Bacterial Robotics, visit its web site at http://BacterialRobotics.com.

Contact 

Jason E. Barkeloo
CEO
+1.513.252.2901
Twitter:  @BactoBot at http://twitter.com/BactoBot
http://BacterialRobotics.com/contact/
info(at)BacterialRobotics.com

###

We Believe

Open Therapeutics crowdsources orphan and dormant therapeutic intellectual properties (IP) to scientists around the world. The goal is advancing research that ordinarily has not generated a public value or been recognized. This approach particularly helps underserved scientists to collaborate with their more financially capable colleagues.

How open science helps researchers succeed:

Open access, open data, open source, and other open scholarship practices are growing in popularity and necessity. However, widespread adoption of these practices has not yet been achieved. One reason is that researchers are uncertain about how sharing their work will affect their careers.

The review of the literature demonstrates that open science is associated with increases in citations, media attention, potential collaborators, job opportunities, and funding opportunities. These findings are evidence that open science practices bring significant benefits to researchers relative to more traditional closed practices.

Secured By miniOrange